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and resistance of a newly established human
gastrointestinal stromal tumour xenograft model
to treatment with tyrosine kinase inhibitors
Thomas Van Looy1, Yemarshet Kelemework Gebreyohannes1, Agnieszka Wozniak1, Jasmien Cornillie1,2,
Jasmien Wellens1, Haifu Li1, Ulla Vanleeuw1, Giuseppe Floris3, Maria Debiec-Rychter4, Raf Sciot3 and
Patrick Schöffski1,2*Abstract
Background: Acquired resistance to tyrosine kinase inhibitors (TKIs) in gastrointestinal stromal tumours (GISTs) is
most commonly caused by secondary KIT or PDGFRA mutations. In this study we characterize a newly established
GIST xenograft model, UZLX-GIST9, and evaluate the in vivo response of the model to standard TKIs (imatinib,
sunitinib, and regorafenib).
Methods: Tumour fragments from a metastatic lesion of a GIST patient clinically progressing after treatment with
imatinib, sunitinib and regorafenib were engrafted in a nude, immunodeficient mouse. Upon sequential passaging
from mouse to mouse, tumour fragments were collected for histopathological and molecular characterization. The
sensitivity of the model to treatment with TKIs was evaluated in 28 mice [passage 2 (n = 8), passage 4 (n = 20), 41
tumours]. Mice were grouped as follows: control (untreated), imatinib (50 mg/kg/BID), imatinib (100 mg/kg/BID),
sunitinib (40 mg/kg/QD), and regorafenib (30 mg/kg/QD). After three weeks of oral treatment, tumours were
collected for subsequent analysis. The efficacy of treatment was assessed by tumour volume, histopathology and
Western immunoblotting.
Results: UZLX-GIST9 maintains the same typical morphological features and immunohistochemical characteristics
as the original patient biopsy and expresses CD117 and DOG1. The KIT mutational profile (p.P577del + W557LfsX5+
D820G) remains the same as the original tissue sample originating from an intraspinal metastatic site. Three week
treatment with different TKIs showed that the model is resistant to imatinib. Sunitinib induces tumour growth delay
and regorafenib reduces the tumour burden by 30% as compared to control animals. While none of the TKIs had a
significant effect on cell proliferation or cell survival, a remarkable increase of necrosis and significant reduction of
microvessel density was observed under sunitinib and regorafenib. Western immunoblotting showed a mild
reduction in KIT and AKT activation only in regorafenib treated tumours.
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Conclusions: We established a novel human GIST xenograft, UZLX-GIST9, harbouring KIT exon 11 and 17 mutations
and maintaining the pheno-and genotype of the original tumour. UZLX-GIST9 shows different levels of response to
standard TKIs. This model will help to study TKI resistance and to explore novel treatment approaches for patients
with TKI-resistant GIST.
Keywords: Xenograft, Gastrointestinal stromal tumour, Resistance, Tyrosine kinase inhibitor, Imatinib, Sunitinib,
RegorafenibBackground
Gastrointestinal stromal tumour (GIST) is the most com-
mon sarcoma of the digestive tract and in some European
regions the most frequently occurring mesenchymal malig-
nancy, with an estimated incidence of 12–14.5 per million
people [1-3]. To date, surgery remains the cornerstone in
the clinical management of primary resectable GISTs [4].
However, surgery is not feasible in all patients because of
tumour site, tumour size or due to metastatic spread [5].
Among patients qualifying for primary surgery, 40-50% de-
velops recurrence or metastases during follow-up. In the
vast majority of GISTs, activating mutations in either the
KIT or the PDGFRA (platelet derived growth factor recep-
tor alpha) gene are the main oncogenic drivers [6,7]. These
genes encode for receptor tyrosine kinases (RTKs), and ac-
tivating mutations in the according genes can result in
constitutive activation of intracellular signalling pathways
leading to enhanced cell proliferation and -survival. The
clinical significance of this observation is demonstrated
by the exceptional anti-tumour activity of tyrosine kinase
inhibitors (TKIs) in patients with advanced GISTs. Cur-
rently, imatinib is the standard first-line treatment for
metastatic and unresectable GISTs and is very well toler-
ated in the vast majority of patients [8]. Imatinib is a multi-
targeted TKI inhibiting ABL, KIT and PDGFRA/B [9].
Unfortunately, with time patients with imatinib-sensitive
disease inevitably develop resistance to this agent. Sunitinib
is the approved second-line therapy for patients intolerant
or no longer responding to imatinib [10]. Sunitinib is an
oral multi-targeted TKI with activity against RTKs like KIT,
VEGFR1/2/3 (vascular endothelial growth factor receptor)
and PDGFRA/B, and was shown to increase progression-
free survival as compared to placebo in imatinib-refractory
patients in a clinical phase 3 trial [11-13]. Nevertheless,
with time the majority of patients will also develop progres-
sive disease under treatment with sunitinib [14]. Recently,
regorafenib has been approved by the United States Food
and Drug Administration (FDA) as third-line treatment
for patients with advanced GIST after failure of both
described TKIs. Regorafenib is an orally bioavailable multi-
targeted TKI with known activity against KIT, RET (rear-
ranged during transfection), VEGFR1/2/3, PDGFRβ, FGFR
(fibroblast growth factor receptor) [15]. In a very re-
cent randomized phase 3 clinical trial regorafenib yieldeda significantly better median progression-free survival than
placebo (4.8 versus 0.9 months), in this setting [16]. When
analysing the available phase 3 evidence for all three estab-
lished agents, it is obvious that the time to progression
decreases progressively with every line of TKI treatment.
It seems unlikely that the development of further KIT- or
PDGFRA-targeted TKIs will circumvent the occurrence of
heterogeneous TKI resistance in GISTs [17]. In the major-
ity of resistant GISTs, TKI resistance is mediated by the
occurrence of secondary mutations in KIT or PDGFRA
[17]. Some additional resistance mechanisms have been
described, like genomic amplification of KIT or PDGFRA
genes or a switch of KIT dependency to other RTKs
(e.g., AXL) [18]. Hence, the development of novel GIST
research models characterized by different sensitivity to
standard treatments is very important for the testing of
novel treatment approaches. At present, there are no GIST
xenograft models described in the literature that have
shown resistance to multiple TKIs. For this reason we are
trying to develop novel GIST xenograft models reflecting
the resistance pattern observed in the clinic. Our new
model UZLX-GIST9 is derived from a patient clinically
and radiologically progressing after treatment with ima-
tinib, sunitinib, and regorafenib. In the current study, we
have characterized this model and tested its sensitivity
in vivo to standard treatments.
Methods
Patient history
A 66-year old female patient was diagnosed with a mass
protruding into the gastric lumen and with synchronous
omental metastases. She underwent a total gastrec-
tomy and the pathological examination revealed a GIST
with CD117 (KIT)-immunopositivity. Mutational analysis
showed a KIT exon 11 mutation (p.P577del). The patient
was referred to our hospital 18 months later because of
progressive disease and started the treatment with ima-
tinib 400 mg daily. After 14 months of therapy, disease
progression was observed and the imatinib dose was esca-
lated to 800 mg daily, which also resulted in progressive
disease (new thoracic metastases). Then the second-line
therapy with sunitinib 50 mg daily was started using the
labelled regimen, achieving the stable disease for 3.5 years.
Upon the next disease progression, nilotinib 400 mg p.o.
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col, until disease progression three months later. At that
point, imatinib rechallenge was introduced (400 mg p.o.
daily), but stopped three months later because of disease
progression. The patient was then included in the multi-
center, double-blind, randomized phase III trial comparing
placebo versus regorafenib given at a dose of 160 mg daily,
three weeks on treatment followed by a one-week rest
period [16]. Upon disease progression three months later,
the study treatment was unblinded and the patient was
crossed over from placebo to regorafenib, with the dis-
ease stabilization for one year. At that point, she was
admitted to the hospital with acute muscle weakness
and diminished sensitivity in the lower extremities. Mag-
netic resonance imaging revealed spinal cord com-
pression through direct intraspinal tumour extension.
She underwent urgent surgical decompression, during
which tumour fragments collected was used for the estab-
lishment of the xenograft model. Pathological examination
the diagnosis of metastatic GIST and the mutational
analysis revealed mutations in KIT exon 11 (p.P577del;
W557LfsX5) and exon 17 (p.D820G). The patient eventu-
ally died of disease 4 months later, 10 years after the initial
diagnosis.Establishment of the UZLX-GIST9 xenograft model
In April 2012, tumour tissue from an intraspinal GIST
metastatic site was collected in culture medium immedi-
ately after surgery. The xenografting of patient-derived
mesenchymal tumour material is approved by the Medical
Ethics Committee, University Hospitals Leuven (S53483).
The tumour specimen was cut in small fragments of
50-100 mm3 and immediately implanted subcutaneously
on both flanks of 1 nude NMRI nude mice (Janvier). After
successful engraftment and growth of the tumour, the
xenograft model was called UZLX-GIST9. The xenograft
could be maintained by serial passaging.Molecular characterization
DNA isolation from frozen fragments originating from
UZLX-GIST9 ex-mouse tumours was performed using
QIAamp DNA Mini Kit (Qiagen). KIT mutational analysis
was done as previously described, using [ENSG00000157404]
as the reference sequence [19].Table 1 Description of treatment groups
Trea
Control Imatinib Im
Passage N Dose N Dose N
2 2 Untreated 3 50 mg/kg/BID n/a
4 6 Untreated 4 50 mg/kg/BID 4 1
N = number of mice; n/a = not available.Drugs and reagents
Imatinib, sunitinib, and regorafenib were purchased from
Sequoia Research Products Ltd., and were dissolved in
sterile water, citric buffer (pH 3.5), and 125 mM polyethyl-
ene glycol 400/methane sulphonic acid (80/20) respect-
ively. All solutions were stored at 4°C and protected from
light.
The following primary antibodies were used for Western
immunoblotting and immunohistochemistry (IHC): phospho-
Y719 KIT (pKIT Y719), phospho-S473 AKT (pAKT), AKT,
alpha-tubulin, phospho-T202/Y204 MAPK (pMAPK),
p42/44 MAPK, phospho-S65 4E-BP1 (p4E-BP1), 4E-BP1,
phospho-Histone H3 (pHH3) (Cell Signaling Technologies);
p-Y703 KIT (pKIT Y703; Invitrogen); KIT (DAKO); beta-
actin (Sigma-Aldrich); cleaved PARP (Cl-PARP; Abcam);
Ki-67 (Thermoscientific); and DOG1 (discovered on GIST-
1; Novocastra). For Western immunoblotting horse radish
peroxidase (HRP)-conjugated antibodies were used, band
visualization was performed using Western Lightning®
Plus-ECL (PerkinElmer). Signalstain® boost IHC detection
reagent (Cell Signaling Technologies), Envision + system,
3′diaminobenzidine-tetrahydrochloride (DAB) (both from
DAKO) and anti-rabbit or anti-mouse antibodies were
purchased for IHC. To detect mouse vessels a rat specific
anti-mouse CD31 antibody (Dianova) was used, with bio-
tinylated anti-rat antibodies, Avidin/Biotin Blocking Kit
and VECTASTAIN Elite ABC Kit (all Vector Laboratories)
in combination with DAB.
Evaluation of TKI response
For the in vivo evaluation of TKI sensitivity 28 mice [pas-
sage 2 (n = 8) and passage 4 (n = 20)] were subcutaneously
engrafted in both flanks with UZLX-GIST9 and were used
in two subsequent experiments. A detailed overview of
treatment groups and schedules can be found in Table 1.
Assessment of tumour volume and mouse body weight
was normalized for baseline values and performed as pre-
viously described [20-23]. After three weeks of treatment
mice were sacrificed, and tumour specimens were snap
frozen in liquid nitrogen or fixed in 4% buffered formalde-
hyde for further histological and molecular analysis.
Histopathology
Fixed tumour specimens were embedded in paraffin
blocks and cut into 4 μm sections on the Microm HMtment group
atinib Sunitinib Regorafenib
Dose N Dose N Dose
n/a 3 40 mg/kg/QD n/a n/a
00 mg/kg/BID n/a n/a 6 30 mg/kg/QD
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& E) or IHC. Histological response (HR) was graded by
assessing the magnitude of necrosis, fibrosis and myxoid
degeneration: grade 1 (0%–10%), grade 2 (>10% and ≤50%),
grade 3 (>50% and ≤90%), and grade 4 (>90%) as described
before [24,25]. Assessment of mitotic and apoptotic activity
was done by counting mitotic figures and apoptotic cells in
10 high power fields (HPF; 400-fold magnification) on H &
E staining. Additionally, mitotic and apoptotic activity were
assessed by counting respectively pHH3 and Cl-PARP
positive cells in 10 HPF. On Ki-67 immunostainings the
proliferative activity was scored as the average percentage of
stained tumour cells in 5 digital microscopic pictures taken
at 400-fold magnification. Microvessel density (MVD) was
calculated as the average number of CD31stained vessels in
5 microscopic fields at 200-fold magnification. An Olympus
LH-30 M microscope equipped with Color View digital
camera was used for all analyses, and Cell D imaging soft-
ware was utilized for picture analysis (all Olympus).
Western immunoblotting
For Western immunoblotting, tumour lysates were pre-
pared from snap frozen tumour specimen as described
previously [22]. Chemiluminescence levels were captured
using FUJI-LAS mini 3000 system (Fujifilm).
Statistical analysis
Wilcoxon’s matched paired (WMP) test was used to com-
pare tumour volumes on day 0 (baseline) versus the lastFigure 1 Haematoxylin and eosin stainings and immunostainings of p
H & E stainings at 400X magnification of original intraspinal GIST metastasi
UZLX-GIST9 tumour showing acellular zone (C). CD117 immunostaining
(D) and UZLX-GIST9 xenograft (E). DOG1 staining of UZLX-GIST9 tumours (F).day of the experiment. The comparison between differ-
ent treatment groups was performed using the Mann–
Whitney U (MWU) test. The statistical significance level
was defined as p < 0.05 and the STATISTICA software
(Stat Soft, version 12.0) was used for all calculations.
Results
Histopathological and molecular characteristics
Since April 2012, the UZLX-GIST9 xenograft model has
been maintained by sequential transplantations in NMRI
nude mice and currently reached the 7th passage. Histo-
pathological evaluation showed a similar morphological
appearance of the ex-mouse UZLX-GIST9 tumours as
compared to the original intraspinal GIST metastatic
sample obtained from the patient. Microscopic analysis
revealed a predominantly spindle cell morphology and
diffuse CD117 (KIT) immunoreactivity in the original
GIST metastasis and in ex-mouse tumours (Figure 1A,
B, D, E), characteristics also observed in the original pri-
mary gastric GIST lesion. In addition, the UZLX-GIST9
model displayed strong positivity for DOG1, which is de-
scribed as a highly sensitive and specific marker for
GIST diagnosis (Figure 1F) [26].
In general, the histopathological evaluation of UZLX-
GIST9 displayed some variability with regards to tumour
morphology throughout the tumour sections, revealing
tumour areas with high cellular density and more vacuo-
lated regions (Figure 1C). In the latter, a more promin-
ent mitotic activity was observed on both H & E and onatient biopsy and UZLX-GIST9 xenograft tumours (passage 4).
s (A), and the UZLX-GIST9 xenograft model (B). H & E staining
of the patient specimen obtained during neurosurgical intervention
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were commonly observed throughout the tumour area
and some apoptotic clustering was observed in surround-
ing areas (data not shown).
The mutational analysis of UZLX-GIST9 xenografts re-
vealed the same KIT exon 11 (p.P577del; W557LfsX5)
and exon 17 (p.D820G) mutations as found in the original
GIST intraspinal metastasis which was used for engraft-
ment. The mutational profile remained stable throughout
the different passages in the mice.
Xenograft sensitivity to standard TKIs
Tumour volume assessment
The sensitivity of the UZLX-GIST9 model to standard
TKI treatments was evaluated in vivo. In general, the
tumour burden increased steadily in untreated and ima-
tinib treated cohorts, showing a relative increase to 282,
278, and 238% for untreated, imatinib 50 mg/kg/BID
and imatinib 100 mg/kg/BID treated animals as com-
pared to baseline (p < 0.05 for all, WMP test) (Figure 2).
No significant difference between relative tumour vol-
umes of untreated and imatinib treated tumour was ob-
served (p > 0.05, MWU test), indicating resistance of the
model to the drug. In contrast, sunitinib delayed tumour
growth of the xenograft (p = 0.068, WMP test) and rego-
rafenib reduced the tumour volume to 70% of the ori-
ginal size (p < 0.05, WMP test) (Figure 2).
Histopathologic evaluation
Histologic response (HR) was assessed by evaluating the
magnitude of necrosis, fibrosis and myxoid degenerationFigure 2 Relative evolution of tumour volume in UZLX-GIST9 xenogra
evolution are displayed as means and standard error of the means.on H & E stainings of tumours collected at the end of the
in vivo experiments. HR to TKIs in UZLX-GIST9 was
mainly characterized by induction of necrosis. In the
imatinib-treated cohorts only minimal histological changes
were observed, whereas sunitinib yielded grade 2 HR
in 75% of the tumours. Importantly, under regorafenib
we observed grade 2 or even 3 HR in almost 80% of tu-
mours (Figure 3).
Untreated UZLX-GIST9 tumours are characterized by
brisk mitotic activity (39 mitotic figures/10 HPF on aver-
age) on H & E staining. Neither TKI treatment induced a
reduction in mitotic activity; rather a slight increase of mi-
totic activity was observed under TKI treatment, which
was even statistically significant in the regorafenib treated
cohort (Table 2). No significant induction of apoptotic ac-
tivity was observed, regardless of the treatment adminis-
tered (Table 2). Observations on H & E were confirmed
by pHH3, Ki-67 and Cl-PARP immunostainings (Table 2).
MVD analysis showed that none of the imatinib regi-
ments significantly lowered vessel density as compared to
untreated control tumours. In contrast, both sunitinib and
regorafenib yielded a 1.4 reduction of microvessel density,
which was significant when compared to control (p < 0.05,
MWU) (Table 2).
Assessment of oncogenic signalling in response to
treatment
By Western immunoblotting we observed expression of
KIT and its main signalling mediators in all untreated
UZLX-GIST9 tumours (Figure 4). In general, imatinib-
and sunitinib-treated cohorts did not show a remarkablefts under treatment with different TKIs. Data for tumour volume
Figure 3 Assessment of histologic response of UZLX-GIST9 during treatment with different TKIs. Histologic response was graded by
assessing the magnitude of necrosis, myxoid degeneration, and/or fibrosis on H & E staining: grade 1 (0%–10%), grade 2 (>10% and ≤50%),
grade 3 (>50% and ≤90%), and grade 4 (>90%) [24,25].
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rafenib, we observed a mild reduction of KIT activation
and a slight inhibition of AKT and 4E-BP1 phosphoryl-
ation (Figure 4).
Discussion
Imatinib treatment in GIST is a paradigm for the use of
targeted treatments in solid tumours. Nevertheless, des-
pite the remarkable effects of this and other TKIs in GIST,
with time the vast majority of patients will inevitably de-
velop resistance against these agents [17]. Importantly, pa-
tients progressing under or being intolerant to imatinib,
sunitinib and regorafenib are left without any established
standard treatment option. Hence, the development of
novel therapeutic options is an unmet medical need. Reli-
able in vitro and in vivo models are required to test new
agents and assess the molecular mechanism of action of
innovative drugs.
To date, the number of GIST xenograft models avail-
able for research is rather limited. A few xenografts haveTable 2 Histological assessment of proliferative and apoptoti
after three weeks of treatment
Mitotic and proliferative activity
H & E pHH3
Imatinib 50 mg/kg/BID ↑1.1 =
Imatinib 100 mg/kg/BID ↑1.1 ↑1.1
Sunitinib 40 mg/kg/QD = ↑1.2
Regorafenib 30 mg/kg/QD ↑1.6* ↑1.5
Results are shown as fold changes in comparison with control, arrows indicate incre
assessment; *P < 0.05 (compared to control). H & E - haematoxylin and eosin stainin
PARP immunostaining.been established upon subcutaneous injection of GIST-T1,
GIST48, GIST430, GIST882 or GIST882Ly cell lines
[20,22,27-29]. Of these cell line-derived xenografts GIST48
and GIST430 are described as being resistant to imatinib,
although both have shown mild to moderate responses to
imatinib in some published in vivo experiments [20,27].
Only a few research groups, including our own, have been
able to establish GIST xenografts based on patient-derived
biopsies [20-23,30-32]. Of these, only the model estab-
lished by Revheim and colleagues is characterized by a sec-
ondary KIT exon 17 mutation [30]. The latter model has
shown tumour growth under imatinib treatment, although
imatinib treatment of this model delayed tumour growth
when compared to untreated tumours [33].
Here we are presenting data from a novel GIST xenograft
model (UZLX-GIST9) based on a tumour biopsy derived
from a patient who had been treated for almost 10 years
with a variety of TKIs, including imatinib, sunitinib, rego-
rafenib and nilotinib. To date, the new model is maintained
for over two years and 7 passages and continues to grow.c activity and microvessel density in tumours collected
Apoptotic activity Microvessel density
Ki-67 H & E Cl-PARP CD31
= ↓1.1 ↑1.1 =
↑1.1 ↓1.3 ↑1.3 =
↑1.1 ↓1.4 ↓1.3 ↓1.4*
↑1.1 ↑1.1 ↑1.4 ↓1.4*
ase (↑) or decrease (↓). Mann–Whitney U test was performed for statistical
g, pHH3 - phospho-histone-H3 immunostaining; Cl-PARP - cleaved
Figure 4 Western analysis of the impact of different TKIs on KIT signalling in UZLX-GIST9.
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tochemical and molecular features of the original intrasp-
inal GIST metastasis with spindle cell morphology, diffuse
CD117 and DOG1 immunoreactivity. The mutational
analysis of the xenograft shows KIT exon 11 and exon 17
mutations (p.P577del; W557LfsX5; D820G), suggesting re-
sistance to commonly used TKIs.
Indeed, we could show imatinib resistance in the dose
range tested. Conversely, the model still showed some
level of response to other TKIs (sunitinib and regorafenib),
even though we did not observe any anti-mitotic or pro-
apoptotic effects of the tested agents. Sunitinib yielded
tumour growth delay and regorafenib induced some re-
gression in tumour volume. Most likely, these effects on
tumour burden are related to the prominent induction of
necrosis observed under regorafenib and sunitinib, which
was not seen under imatinib treatment. In addition, only
in regorafenib treated tumours a slight inhibition of KIT
and AKT activation was observed. The mild increase in
mitotic activity in the viable tumour areas under regorafe-
nib treatment is most likely the result of selective pressure
by the high degree of necrosis observed in these tumours
and the multi-targeted nature of the TKI, resulting in the
selection of the most aggressive and mitotically active
tumour cells.
These findings provide evidence for the characterization
of UZLX-GIST9 as a truly imatinib-resistant model.Intriguingly, despite the lack of a seemingly direct inhibi-
tory effect on cell proliferation and survival we observed a
decrease in tumour growth rate or even tumour volume
reduction for sunitinib and regorafenib, respectively. Both
drugs are known to have anti-angiogenic effects, and
we have shown that both drugs significantly reduced
MVD in the newly established GIST xenograft model
when compared to untreated control tumours [11,15].
We therefore postulate that the effect on tumour vol-
ume caused by these drugs could partially result from
the antivascular capacity of these drugs; the observation of
necrosis as a feature of response supports this hypothesis.
Our findings suggest that some of the clinical effects of re-
gorafenib in imatinib-resistant GIST may not be mediated
through suppression of KIT signalling. These results war-
rant further research related to the mechanisms of the
regorafenib-induced clinical benefit observed in imatinib-
and sunitinib-resistant GIST patients [16]. Addition-
ally, further studies of more potent or more selective
anti-angiogenic compounds in the novel UZLX-GIST9
model could prove valuable.
Conclusions
In summary, a novel human GIST xenograft with KIT
exon 11 and exon 17 mutations has been established. This
novel xenograft model resembles the morphological and
molecular features of the original tumour that had failed
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three approved agents for the therapy of advanced, meta-
static GIST. The model exhibits strong imatinib resist-
ance; tumour growth and high tumour cell proliferation
was observed under sunitinib. Regorafenib shows signifi-
cant anti-tumour effects in this model, which seem inde-
pendent of KIT inhibition. Furthermore, both sunitinib
and regorafenib significantly lower MVD and induce
necrosis in the UZLX-GIST9 model. Overall, we present a
novel GIST research tool which will be very valuable for the
development of novel experimental treatment approaches
and hopefully translate into direct patient benefit.
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